NCT03267576View on ClinicalTrials.gov

An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin

PHASE4CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

October 27, 2017

Primary Completion Date

October 1, 2018

Study Completion Date

October 1, 2018

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Canagliflozin 300 mg

Participants will receive canagliflozin 300 mg oral tablet once-daily for 28 days.

DRUG

Sitagliptin 100 mg

Participants will receive sitagliptin 100 mg oral tablet once-daily for 28 days.

DRUG

Metformin

Participants will receive metformin at a stable dose of \>= 1500 mg/day throughout the study including the washout period between each intervention.

Trial Locations (5)

14080

Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City

44150

Consultorio Privado, Guadalajara

44600

Investigación Clínica Especializada, Guadalajara

44650

Consultorio Privado en Unidad de Patología Clínica, Guadalajara

64460

Hospital Universitario 'Dr. Jose Eleuterio Gonzalez', Monterrey

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT03267576 - An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin | Biotech Hunter | Biotech Hunter